Unacylated ghrelin and AZP531 suppress the 3D growth of breast cancers

Breast cancer is the most common type of cancer in women and notwithstanding important therapeutic advances, it remains the second leading cause of cancer-related death in the US. Despite extensive research relating to the hormone ghrelin, responsible for the stimulation of growth hormone release and appetite, little is known of the effects of its unacylated form, especially in cancer. One major area of research relates to its reported effects to increase insulin sensitivity in diabetics, this being the basis for the development of unacylated ghrelin analog, AZP531 or livoletide, now in clinical trials for the treatment of Prader-Willi Syndrome. The mechanism of action of unacylated ghrelin is largely uncharacterized, in any system, because it does not bind to or activate the cognate ghrelin receptor, GHSR1a. The present study aimed to characterize effects of unacylated ghrelin on breast cancer cells, define its mechanism of action, and explore the therapeutic potential of unacylated ghrelin or analog AZP531. We report potent effects of unacylated ghrelin, at picomolar doses, on the growth of breast cancer cells, dependent on 3D culture and activation of Gαi. Suppression of MAPK signaling by unacylated ghrelin leads to cell cycle arrest and apoptosis. AZP531 also suppresses the growth of breast cancer cells in vitro and in xenografts, and may be a novel approach for the safe and effective treatment of breast cancer.

[1]  D. Potvin,et al.  AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial , 2018, PloS one.

[2]  J. Furness,et al.  Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  J. Furness,et al.  Ghrelin and Breast Cancer: Emerging Roles in Obesity, Estrogen Regulation, and Cancer , 2017, Front. Oncol..

[4]  T. Abribat,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP‐531, a first‐in‐class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[5]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[6]  S. Hiscox,et al.  3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response , 2016, BMC Cancer.

[7]  Ashutosh Kumar Singh,et al.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. , 2015, Biomaterials.

[8]  C. Barrios,et al.  Optimal management of hormone receptor positive metastatic breast cancer in 2016 , 2015, Therapeutic advances in medical oncology.

[9]  Ki-Chun Yoo,et al.  Activation of KRAS promotes the mesenchymal features of basal-type breast cancer , 2015, Experimental & Molecular Medicine.

[10]  J. Furness,et al.  Novel and Conventional Receptors for Ghrelin, Desacyl-Ghrelin, and Pharmacologically Related Compounds , 2014, Pharmacological Reviews.

[11]  J. Furness,et al.  Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism , 2014, Breast Cancer Research and Treatment.

[12]  Justin M Balko,et al.  Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. , 2014, Discovery medicine.

[13]  B. Weigelt,et al.  The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. , 2014, Advanced drug delivery reviews.

[14]  H. Tinsley,et al.  The Role of Cyclic Nucleotide Signaling Pathways in Cancer: Targets for Prevention and Treatment , 2014, Cancers.

[15]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[16]  P. Lønning,et al.  Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved , 2013, Endocrine-related cancer.

[17]  P. McIntyre,et al.  Sites of action of ghrelin receptor ligands in cardiovascular control. , 2012, American journal of physiology. Heart and circulatory physiology.

[18]  E. Ghigo,et al.  Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. , 2012, European journal of endocrinology.

[19]  K. Jirström,et al.  Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer , 2012, Acta oncologica.

[20]  M. Mulholland,et al.  Effect of des-acyl ghrelin on adiposity and glucose metabolism. , 2008, Endocrinology.

[21]  S. Cohen,et al.  Connecting proliferation and apoptosis in development and disease , 2004, Nature Reviews Molecular Cell Biology.

[22]  R. McPherson,et al.  The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  M. Papotti,et al.  Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  Prahlad T. Ram,et al.  Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Miller,et al.  Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. , 1996, European journal of cancer.

[26]  B. Katzenellenbogen,et al.  Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Fontana,et al.  Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. , 1987, Journal of the National Cancer Institute.

[28]  U. Eppenberger,et al.  Growth stimulation of human breast cancer MCF-7 cells by dibutyryl cyclic AMP. , 1983, Cell biology international reports.

[29]  Y. Cho‐Chung,et al.  Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. , 1981, Science.

[30]  T. Wisenbaugh,et al.  Elevated cyclic AMP levels in human breast-cancer tissue. , 1974, Journal of the National Cancer Institute.

[31]  K. Kangawa,et al.  Therapeutic potential of ghrelin and des-acyl ghrelin against chemotherapy-induced cardiotoxicity. , 2017, Endocrine journal.

[32]  S. Fox,et al.  Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women , 2013, Breast Cancer Research and Treatment.